Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Prenatal Risk Of Toxicity Evaluation for Clinical Translation

Project description

Closing the gap in prenatal drug safety research

Drug safety in pregnancy is one area that still constitutes a major blind spot in the field of medicine. Pregnant women have to take crucial decisions on issues related to their well-being in cases where limited information is provided on the impact of a certain medication. This is because most medications are not tested on pregnant women. In order to address this issue, the ERC-funded PROTECT project aims to develop a new means of assessing the safety of medications used by pregnant women. A novel approach is necessary due to the fact that pregnant women cannot be involved in clinical trials, while animal research proves ineffective in this respect.

Objective

Drug safety during pregnancy remains one of the most underexplored and high-risk areas in medicine.
Pregnant women are routinely excluded from clinical trials, and animal models often fail to predict human outcomes, leaving a critical blind spot in assessing fetal drug toxicity. As a result, many therapies are withheld during pregnancy due to insufficient safety data, not demonstrated harm, creating both a medical and societal gap.
PROTECT proposes the first clinically adaptable, high-throughput 3D-bioprinted in vitro platform to evaluate drug toxicity on human fetal tissues during mid-to-late gestation. The system leverages prenatal cells combined with advanced bioprinting to create reproducible 3D tissue models enabling systematic testing under conditions compatible with pharmaceutical and regulatory workflows.
The project will pursue three technological objectives: (1) optimize a robust 3D-bioprinting protocol to ensure reproducibility and scalability; (2) develop a functional testing pipeline using benchmark compounds to validate predictive value; and (3) upscale the model to achieve the throughput required for industrial use.
In parallel, a business validation track will analyze stakeholder needs, market dynamics, regulatory frameworks, and alternative business models (product sales, testing-as-a-service, licensing). This will ensure that PROTECT is not only scientifically robust but also aligned with user requirements and positioned for commercialization.
By bridging a long-standing gap in prenatal toxicology, PROTECT aims to deliver safer and more inclusive drug development, reduce reliance on animal testing, and prepare the ground for a dedicated spin-out company capable of driving clinical and industrial adoption.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

POLITECNICO DI MILANO
Net EU contribution
€ 110 000,00
Address
PIAZZA LEONARDO DA VINCI 32
20133 Milano
Italy
Region
Nord-Ovest Lombardia Milano
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (2)